Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Antithrombin III advances to phase II

Dec. 11, 1996

Allelix reports thrombospondin-derived antihemorrhagic peptide

Dec. 11, 1996

New thrombin inhibitors under study at Merck & Co.

Dec. 9, 1996

Vascular Therapeutics licenses Recordati compound

Dec. 4, 1996

Merck reveals new thrombin inhibitor series

Dec. 3, 1996

3DP seeks partners for protease inhibitor discovery program

Nov. 29, 1996

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Nov. 28, 1996

Potent, orally active antiplatelet agent discovered by Merck & Co.

Nov. 28, 1996

Natural antiplatelet agent discovered at Kitasato Institute

Nov. 28, 1996

RESTORE trial results presented at AHA meeting

Nov. 22, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...